PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Vedolizumab is an anti-inflammatory monoclonal antibody that exclusively targets the α4β7 integrin. We aimed to systematically review the efficacy and safety of vedolizumab for patients with inflammatory bowel diseases (IBDs). PubMed, EMBASE, and the Cochrane Library were searched up to May 2014. Ra...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Medicine (Baltimore)
Autors principals: Wang, Man Cai, Zhang, Ling Yi, Han, Wei, Shao, Yuan, Chen, Mo, Ni, Rui, Wang, Gen Nian, Wei, Feng Xian, Zhang, Ya Wu, Xu, Xiao Dong, Zhang, You Cheng
Format: Artigo
Idioma:Inglês
Publicat: Wolters Kluwer Health 2014
Matèries:
4200
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4603082/
https://ncbi.nlm.nih.gov/pubmed/25526490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000000326
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars